Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Plus Anlotinib in Recurrent/Metastatic Cervical Cancer
NCT05817214Phase 2Recruiting
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Feb 2023
- Primary completion
- Nov 2025
- Modality
- Bispecific Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab and anlotinib in Cervical Cancer (CC), sponsored by Zhongnan Hospital of Wuhan University. Primary endpoint: Objective Response Rate up to 2 years. Started Feb 2023; status: recruiting.
02
Drugs
cadonilimabanlotinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05817214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05817214.